Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn’s disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencepha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2017-12-01
|
| Series: | Case Reports in Gastroenterology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/484199 |
| id |
doaj-017d559fc6bf45a180454fb48d58eb28 |
|---|---|
| record_format |
Article |
| spelling |
doaj-017d559fc6bf45a180454fb48d58eb282020-11-25T00:55:13ZengKarger PublishersCase Reports in Gastroenterology1662-06312017-12-0111378679010.1159/000484199484199Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?Judy A. TrieuMohammad BilalGurinder LuthraVedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn’s disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies. We present the case of a patient who developed an ovarian teratoma after initiation of vedolizumab therapy.https://www.karger.com/Article/FullText/484199VedolizumabOvarian teratoma |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Judy A. Trieu Mohammad Bilal Gurinder Luthra |
| spellingShingle |
Judy A. Trieu Mohammad Bilal Gurinder Luthra Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? Case Reports in Gastroenterology Vedolizumab Ovarian teratoma |
| author_facet |
Judy A. Trieu Mohammad Bilal Gurinder Luthra |
| author_sort |
Judy A. Trieu |
| title |
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? |
| title_short |
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? |
| title_full |
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? |
| title_fullStr |
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? |
| title_full_unstemmed |
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma? |
| title_sort |
vedolizumab as a potential culprit in the development of ovarian teratoma? |
| publisher |
Karger Publishers |
| series |
Case Reports in Gastroenterology |
| issn |
1662-0631 |
| publishDate |
2017-12-01 |
| description |
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn’s disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies. We present the case of a patient who developed an ovarian teratoma after initiation of vedolizumab therapy. |
| topic |
Vedolizumab Ovarian teratoma |
| url |
https://www.karger.com/Article/FullText/484199 |
| work_keys_str_mv |
AT judyatrieu vedolizumabasapotentialculpritinthedevelopmentofovarianteratoma AT mohammadbilal vedolizumabasapotentialculpritinthedevelopmentofovarianteratoma AT gurinderluthra vedolizumabasapotentialculpritinthedevelopmentofovarianteratoma |
| _version_ |
1725231341581107200 |